Online citations, reference lists, and bibliographies.

Chronic Proton Pump Inihibitor Therapy And Calcium Metabolism

Yu-Xiao Yang
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Proton pump inhibitors (PPIs) have been widely used since their introduction in the late 1980s because they are highly effective for acid-related conditions. However, some recent epidemiological studies have suggested a positive association between PPI therapy and the risk of osteoporotic fractures. The potential mechanisms underlying this association may be related to the physiologic effects of chronic acid suppression on calcium metabolism. First, chronic hypergastrinemia induced by PPI therapy may lead to parathyroid hyperplasia, resulting in increased loss of calcium from the bone. Second, profound gastric acid suppression may reduce the bioavailability of calcium for intestinal absorption. I will review the published evidence regarding these potential links and discuss their clinical implications.
This paper references
10.1016/S0899-9007(97)83011-0
Calcium and osteoporosis.
B. Nordin (1997)
Dietary intake of selected vitamins for the United States population: 1999-2000.
R. Ervin (2004)
10.3109/00365528909091254
Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine.
G. Brunner (1989)
10.1053/j.gastro.2010.03.055
Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
D. Corley (2010)
10.1007/s00198-003-1493-1
Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures
B. Nordin (2004)
10.1016/0016-5085(90)90946-X
Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis.
J. B. Jansen (1990)
10.1093/jn/131.4.1344S
Factors influencing the measurement of bioavailability, taking calcium as a model.
R. Heaney (2001)
10.3177/JNSV.44.869
Effect of L-lactic acid on the absorption of calcium in gastrectomized rats.
O. Chonan (1998)
10.1007/BF01297018
Long-term maintenance treatment of reflux esophagitis with omeprazole
H. Koop (1991)
10.1056/NEJM198708273170903
Gastrointestinal absorption of calcium from milk and calcium salts.
M. Sheikh (1987)
10.1007/s00198-010-1337-8
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
S. Pouwels (2010)
10.1007/s002239900325
Chicken Parathyroid Hormone Gene Expression in Response to Gastrin, Omeprazole, Ergocalciferol, and Restricted Food Intake
R. Gagnemo-Persson (1997)
10.3109/00365528809090202
Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment.
T. Lind (1988)
10.1001/archinte.1991.00400100100017
A model of lifetime osteoporosis impact.
E. Chrischilles (1991)
10.7326/0003-4819-132-5-200003070-00003
Low Fractional Calcium Absorption Increases the Risk for Hip Fracture in Women with Low Calcium Intake
K. Ensrud (2000)
10.1210/jcem-55-2-219
Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity.
A. F. Stewart (1982)
10.1177/009127000004001108
Pharmacokinetic and Pharmacodynamic Comparison of Two Calcium Supplements in Postmenopausal Women
H. Heller (2000)
10.3109/00365527709181713
The parathyroid glands in experimentally induced hypergastrinemia in the rat.
L. Grimelius (1977)
10.1136/bmj.e372
Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study
H. Khalili (2012)
10.1093/AJE/KWH207
Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000.
K. Radimer (2004)
10.1001/JAMA.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
10.1007/s00223-008-9170-1
Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults
E. Yu (2008)
10.3109/00365529109093190
Session 5: Trophic Effects of Gastrin
R. Håkanson (1991)
10.1080/003655201750422585
Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats.
G. Cui (2001)
10.1016/J.AMJMED.2005.02.007
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
M. B. O'Connell (2005)
10.1093/ajcn/49.2.372
Meal effects on calcium absorption.
R. Heaney (1989)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
P. Ivanovich (1967)
10.1136/gut.26.3.252
Regulation of vitamin D and calcium metabolism after gastrectomy.
L. Nilas (1985)
10.1056/NEJM198507113130202
Calcium absorption and achlorhydria.
R. Recker (1985)
10.1172/JCI111254
An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.
G. Bo-Linn (1984)
10.1002/jbmr.166
Do Proton Pump Inhibitors Decrease Calcium Absorption?
K. Hansen (2010)
10.3109/00365529409092460
Growth of the parathyroid glands in omeprazole-treated chickens.
R. Gagnemo-Persson (1994)
10.1007/s00223-006-0021-7
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
P. Vestergaard (2006)
10.1007/BF01352010
Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans
K. Mizunashi (2005)
10.1007/978-1-4684-9111-1_12
Low gastric hydrochloric acid secretion and mineral bioavailability.
E. Champagne (1989)
10.1592/phco.28.8.951
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
J. Kaye (2008)
10.1046/J.1525-1594.1998.06200.X
Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis.
P. Hardy (1998)
10.1046/J.1532-5415.2002.50455.X
Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study.
C. Leibson (2002)
10.1111/j.1572-0241.1999.1123_a.x
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
K. Devault (1999)
10.1016/0016-5085(93)90344-C
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.
R. Lamberts (1993)
10.1172/JCI118993
Processing and proliferative effects of human progastrin in transgenic mice.
T. Wang (1996)
10.1093/ndt/10.8.1376
Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects.
G. Graziani (1995)
10.1111/j.1572-0241.2005.41217.x
Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease
K. Devault (2005)
10.1007/s00198-006-0248-1
Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial
S. Majumdar (2006)
10.1159/000064290
Calcium and Phosphate Plasma Levels in Dialysis Patients after Dietary Ca-P Overload
G. Graziani (2002)
10.1001/archinternmed.2010.94
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
S. Gray (2010)
10.1159/000199610
Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment.
G. Brunner (1988)
10.1046/j.1365-2036.1998.00374.x
Trends in prescribing H2‐receptor antagonists and proton pump inhibitors in primary care
Martín (1998)
10.1136/bmj.317.7156.452
Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database
J. Bashford (1998)
10.1503/cmaj.071330
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
10.3177/JNSV.44.473
Effect of L-lactic acid on calcium absorption in rats fed omeprazole.
O. Chonan (1998)
10.1016/S0140-6736(97)02342-8
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
R. Lindsay (1997)
10.1172/JCI6610
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.
R. Jilka (1999)
10.1111/j.1365-2036.1990.tb00457.x
Serum gastrin levels during long‐term omeprazole treatment
H. Koop (1990)
10.1080/07315724.1995.10718522
Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.
C. Serfaty-Lacrosniere (1995)
10.1159/000200913
Controlled clinical trials of omeprazole in the long-term management of reflux disease.
D. Hetzel (1992)



This paper is referenced by
10.1107/S2053229616004216
Crystal structure and bonding analysis of the first dinuclear calcium(II)-proton-pump inhibitor (PPI) `butterfly molecule': a combined microcrystal synchrotron and DFT study.
Hengjiang Cong (2016)
10.1016/j.pharep.2016.06.012
Effects of long-term administration of pantoprazole on bone mineral density in young male rats.
Agnieszka Matuszewska (2016)
10.1007/978-3-030-27592-1_14
Medical Treatment of GERD
C. Muller (2020)
Effects of Non-Steroidal Anti-Inflammatory Drugs on the Gastrointestinal and Cardiovascular System
G Masclee (2016)
10.1177/8755122518780742
Medications and Micronutrients: Identifying Clinically Relevant Interactions and Addressing Nutritional Needs
Jeffery David Prescott (2018)
10.1016/j.rboe.2015.03.002
Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone☆
G. Yanagihara (2015)
10.1016/j.afos.2019.09.005
Nonpharmacological interventions for osteoporosis treatment: Systematic review of clinical practice guidelines
Roberto Coronado-Zarco (2019)
10.1007/978-3-030-12318-5_5
Medical Management of LPR
Justin Field (2019)
10.1007/s00210-015-1208-0
Pharmacological reports about gastroprotective effects of methanolic extract from leaves of Solidago chilensis (Brazilian arnica) and its components quercitrin and afzelin in rodents
Mariel de Barros (2015)
10.1007/s40266-014-0166-4
A Benefit–Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly
G. Masclee (2014)
10.1001/jamaoto.2013.4505
Causes of emergency department visits following thyroid and parathyroid surgery.
W. Young (2013)
10.1016/J.TCMJ.2014.05.003
Refractory hypocalcemia and hypomagnesemia associated with the use of an oral proton-pump inhibitor in a patient with hypoparathyroidism
Yea-Shin Lin (2015)
10.1007/978-3-319-71181-2
Mandibular Implant Prostheses
E. Emami (2018)
10.1016/J.JEVS.2019.102851
Omeprazole Reduces Calcium Digestibility in Thoroughbred Horses.
Joe D. Pagan (2020)
10.3390/ijerph16091571
Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved
Benjamin Ka Seng Thong (2019)
10.1007/978-94-007-6812-3_7
Gastro-Esophageal Reflux in Neonatology
Keith Barrington (2013)
10.1590/1414-431X20155076
Analysis of fracture healing in osteopenic bone caused by disuse: experimental study
A G Paiva (2016)
10.3109/19390211.2014.950783
Effect of GutsyGumtm, A Novel Gum, on Subjective Ratings of Gastro Esophageal Reflux Following A Refluxogenic Meal
R. Brown (2015)
10.3109/13697137.2015.1103615
Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors
D V Byreddy (2015)
10.1016/J.RBO.2014.05.012
Efeitos da administração em longo prazo do omeprazol sobre a densidade mineral óssea e as propriedades mecânicas do osso
G. Yanagihara (2015)
10.1371/journal.pgen.1005057
Osteopetrorickets due to Snx10 Deficiency in Mice Results from Both Failed Osteoclast Activity and Loss of Gastric Acid-Dependent Calcium Absorption
L. Ye (2015)
10.1016/j.bone.2013.09.014
Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
M. Maggio (2013)
10.1542/peds.2018-2625
Early Acid Suppression Therapy Exposure and Fracture in Young Children
Laura Malchodi (2019)
10.1038/s41598-020-70712-9
Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes
Ya-Shuan Chou (2020)
10.1007/s00774-015-0699-6
Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors
E. Bahtiri (2015)
10.1007/978-94-007-6812-3
Nutrition for the Preterm Neonate
S. Patole (2013)
10.1111/jcpe.12506
Systemic administration of omeprazole interferes with bone healing and implant osseointegration: an in vivo study on rat tibiae.
Ahmed Al Subaie (2016)
10.3389/fendo.2020.00473
Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?
Y. Ghebre (2020)
The Evaluation of omeprazole effect on the sensitivity of 99mTc-MDP bone-seeking to detect simulated closed fracture in the rat’s foot
A. Doroudi (2017)
10.1007/s40272-018-0311-3
Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux
Steven L. Ciciora (2018)
10.1016/j.bone.2013.08.013
Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
B. Abrahamsen (2013)
10.1038/bonekey.2014.69
A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures.
B. Abrahamsen (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar